Overview

Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes

Status:
Completed

Trial end date:
2016-01-01

Target enrollment:

Participant gender:

Summary

This clinical trial studies idarubicin, cytarabine, and pravastatin sodium in treating patients with newly diagnosed acute myeloid leukemia or myelodysplastic syndromes. Drugs used in chemotherapy, such as idarubicin and cytarabine, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Pravastatin sodium may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Giving idarubicin and cytarabine together with pravastatin sodium may kill more cancer cells.

Phase:

N/A

Details

Lead Sponsor:

Fred Hutchinson Cancer Research Center

Collaborator:

National Cancer Institute (NCI)

Treatments:

Cytarabine
Idarubicin
Pravastatin